Get the Stockscreener App
74.18
0.58%
-0.43
After Hours:
74.18
Mirum Pharmaceuticals Inc stock is traded at $74.18, with a volume of 593.39K.
It is down -0.58% in the last 24 hours and up +42.00% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$74.61
Open:
$74.61
24h Volume:
593.39K
Relative Volume:
0.99
Market Cap:
$3.73B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-46.01
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
-1.79%
1M Performance:
+42.00%
6M Performance:
+64.04%
1Y Performance:
+77.46%
1-Day Range:
$73.26
$74.83
1-Week Range:
$73.12
$76.02
52-Week Range:
$36.86
$76.02
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
74.18 | 3.73B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals stock reaches all-time high of 75.8 USD - Investing.com
Real time scanner hits for Mirum Pharmaceuticals Inc. explained2025 Short Interest & Daily Profit Focused Screening - Newser
Does Mirum Pharmaceuticals Inc. show high probability of reboundJuly 2025 Spike Watch & Verified Swing Trading Watchlist - Newser
Signal strength of Mirum Pharmaceuticals Inc. stock in tech scannersEarnings Recap Report & Capital Efficient Trade Techniques - Newser
Multi factor analysis applied to Mirum Pharmaceuticals Inc.Weekly Stock Report & Risk Controlled Swing Alerts - Newser
Chart overlay techniques for tracking Mirum Pharmaceuticals Inc.Market Performance Recap & Smart Money Movement Alerts - Newser
Forecasting Mirum Pharmaceuticals Inc. price range with options dataPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
Is Mirum Pharmaceuticals Inc. impacted by rising ratesSwing Trade & Real-Time Buy Zone Alerts - khodrobank.com
Is Mirum Pharmaceuticals Inc. showing signs of accumulationMarket Movement Recap & High Accuracy Buy Signal Tips - Newser
Does Mirum Pharmaceuticals Inc. have strong fundamentalsJuly 2025 Breakouts & Risk Managed Investment Strategies - khodrobank.com
How high can Mirum Pharmaceuticals Inc. stock goEarnings Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Sentiment analysis tools applied to Mirum Pharmaceuticals Inc.2025 Key Lessons & Daily Technical Forecast Reports - Newser
What are Mirum Pharmaceuticals Inc.’s earnings expectationsPortfolio Growth Summary & High Conviction Buy Zone Alerts - khodrobank.com
Strategies to average down on Mirum Pharmaceuticals Inc.July 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Alagille Syndrome Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Takeda, Mirum Pharmaceuticals, Albireo - Barchart.com
How to interpret RSI for Mirum Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Volume Analysis - Newser
What indicators show strength in Mirum Pharmaceuticals IncWeekly Trend Report & Capital Efficiency Focused Strategies - Newser
Using Ichimoku Cloud for Mirum Pharmaceuticals Inc. technicals2025 Bull vs Bear & Risk Adjusted Buy and Sell Alerts - Newser
Applying big data sentiment scoring on Mirum Pharmaceuticals Inc.July 2025 Decliners & Fast Entry Momentum Alerts - Newser
Is Mirum Pharmaceuticals Inc. stock forming a triangle pattern2025 Major Catalysts & Advanced Technical Analysis Signals - khodrobank.com
Will Mirum Pharmaceuticals Inc. benefit from seasonalityEarnings Risk Report & Capital Protection Trading Alerts - khodrobank.com
Will Mirum Pharmaceuticals Inc. stock hit new highs in YEAR2025 Volatility Report & Safe Swing Trade Setup Alerts - khodrobank.com
What is Mirum Pharmaceuticals Inc. s debt to equity ratio2025 Winners & Losers & AI Powered Buy and Sell Recommendations - khodrobank.com
What’s next for Mirum Pharmaceuticals Inc. stock pricePortfolio Profit Report & Verified Swing Trading Watchlists - Newser
Trend Dashboard Flags Mirum Pharmaceuticals Inc. As Potential Swing Trade getLinesFromResByArray error: size == 0 - thegnnews.com
Can Mirum Pharmaceuticals Inc. deliver consistent dividends2025 Stock Rankings & Free Community Consensus Stock Picks - beatles.ru
Applying Elliott Wave Theory to Mirum Pharmaceuticals Inc.2025 Momentum Check & Free Community Supported Trade Ideas - Newser
What indicators show strength in Mirum Pharmaceuticals Inc.Earnings Miss & Stock Portfolio Risk Management - Newser
Will Mirum Pharmaceuticals Inc. stock recover after recent dropInsider Buying & Expert Verified Stock Movement Alerts - Newser
Using Bollinger Bands to evaluate Mirum Pharmaceuticals Inc.2025 Winners & Losers & Long-Term Growth Plans - Newser
Mirum Pharmaceuticals Inc. Shows Risk Reward Favoring UpsideJuly 2025 Volume & Advanced Technical Signal Analysis - beatles.ru
Visual trend scoring systems applied to Mirum Pharmaceuticals Inc.Trade Entry Summary & Weekly Watchlist of Top Performers - Newser
Mirum Pharmaceuticals (NASDAQ:MIRM) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mirum Pharmaceuticals Inc Stock (MIRM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Aug 11 '25 |
Option Exercise |
2.94 |
40,000 |
117,440 |
178,641 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Aug 11 '25 |
Sale |
62.00 |
40,000 |
2,480,000 |
138,641 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):